Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer
NCT00016549 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is completed. It studies Bevacizumab in Breast Cancer. The registry lists an enrollment of 21 participants at 1 site in 1 country. The registry lists a start date of 13 May 2001 and a primary completion date of 29 Jan 2007.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00016549 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | National Cancer Institute (NCI) |
| Enrollment | 21 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Breast Cancer |
| Drugs | Bevacizumab |
| Start | 13 May 2001 |
| Primary completion | 29 Jan 2007 |
| Study completion | 29 Jan 2007 |
| Last update posted | 2 Jul 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Suparna Wedam, M.D.
National Cancer Institute (NCI)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00016549
Each answer restates registry values shown on this page.
What is NCT00016549?
NCT00016549 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Bevacizumab in Breast Cancer.
Who leads NCT00016549?
The registry names Suparna Wedam, M.D. (principal investigator, National Cancer Institute (NCI)) as the overall official.
Where does NCT00016549 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00016549 study?
The registered drug and biological interventions are Bevacizumab.
When did NCT00016549 end?
The registry lists a primary completion date of 29 Jan 2007 and a study completion date of 29 Jan 2007. The sponsor last updated the record on 2 Jul 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.